{"schemaVersion":"peptidescanner-evidence-bundle/v1","canonicalUrl":"https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json","manifestUrl":"https://peptidescanner.com/evidence/v1/manifest.json","peptide":{"slug":"foxo4-dri","name":"FOXO4-DRI","url":"https://peptidescanner.com/peptides/foxo4-dri/"},"addressing":"objects is keyed by objectPathId. A URL fragment #<objectPathId> on this file names one evidence object. Every version of a record is placed in the bundle of the record's current first peptide.","objectCount":2,"objects":{"pubmed-pmid-33996787-foxo4-dri-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-33996787-foxo4-dri:v1","objectPathId":"pubmed-pmid-33996787-foxo4-dri-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-33996787-foxo4-dri/","json":"https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json#pubmed-pmid-33996787-foxo4-dri-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.md#pubmed-pmid-33996787-foxo4-dri-v1"},"story":{"slug":"pubmed-pmid-33996787-foxo4-dri","version":1,"domain":"Literature metadata","dateInSource":"2022-02-01","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["foxo4-dri"],"peptides":[{"slug":"foxo4-dri","url":"https://peptidescanner.com/peptides/foxo4-dri/"}]},"claims":[{"id":"headline","text":"Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.","sourceIds":["pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a"]},{"id":"summary","text":"PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a"]},{"id":"paragraph-1","text":"PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a"]}],"sources":[{"id":"pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a","name":"PubMed","sourceClass":"A","title":"Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. · retained source version 1:2022-02-01:current:d5f8ee6e316af95181837000f97a1a7561b9724dec5766f7efda10dffd1f695c","url":"https://pubmed.ncbi.nlm.nih.gov/33996787/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7296a39b6860fa24f00644915ea037c53a992723652b7664df8e7c128f8602ee","tierARecordSha256":"a13d5808c165eafcb2d17fa712158209b4623d461b96c241ebee631db460051b"},"integrity":{"algorithm":"sha256","contentSha256":"ba11444bb991bb8ffe956bce784b67058a63a37804aea552c3d077079ace4a15"}},"pubmed-pmid-40593617-foxo4-dri-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-40593617-foxo4-dri:v1","objectPathId":"pubmed-pmid-40593617-foxo4-dri-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-40593617-foxo4-dri/","json":"https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json#pubmed-pmid-40593617-foxo4-dri-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.md#pubmed-pmid-40593617-foxo4-dri-v1"},"story":{"slug":"pubmed-pmid-40593617-foxo4-dri","version":1,"domain":"Literature metadata","dateInSource":"2025-07-04","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["foxo4-dri"],"peptides":[{"slug":"foxo4-dri","url":"https://peptidescanner.com/peptides/foxo4-dri/"}]},"claims":[{"id":"headline","text":"The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.","sourceIds":["pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e"]},{"id":"summary","text":"PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e"]},{"id":"paragraph-1","text":"PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e"]}],"sources":[{"id":"pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e","name":"PubMed","sourceClass":"A","title":"The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. · retained source version 1:2025-07-04:current:abbaa47a024e3ff12fee4ca52627a3f679852ccfd5a2f79f0af0567b8a2ab3ef","url":"https://pubmed.ncbi.nlm.nih.gov/40593617/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"f21ac0f633e28e50df870b594d791a9eb57e0fffba1b952589c5ee3986b5bcb2","tierARecordSha256":"6dcf250497464f472f57436ddf12172ab6b22ac28b27be7a5a098bd32052aafb"},"integrity":{"algorithm":"sha256","contentSha256":"2f16b23ec2352f51bc4f8c1816fde1d5e3ae74eaaee1811bb3a895e37cb3fd5a"}}}}
